Fuzeon Increased Pneumonia Incidence Likely A "Specious" Finding – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The increased incidence of bacterial pneumonia seen with Roche/Trimeris’ Fuzeon may be an artifact of the design of the pivotal trails, FDA suggested in review documents for the HIV therapy.